lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
265 rows where filing_period = "third_quarter", filing_year = 2017 and issue_code = "PHA" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, income_amount, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017836 | ROSE LAW FIRM, A PROFESSIONAL ASSOCIATION 286175f5-0489-42b0-b900-71d2aa0838a3 | 3T | ROSE LAW FIRM, A PROFESSIONAL ASSOCIATION | 78870 | THE INTERNATIONAL ACADEMY OF COMPOUNDING PHARMACISTS | 2017 | third_quarter | PHA | Legislative efforts related to the implementation of the Food, Drug and Cosmetic Act, and the Drug Quality and Security Act (P.L 113-54). Issues related to reimbursement of compounded medications and recommended changes to the Social Security Act; drug pricing (no specific bills). Pharmacy inspection issues and concerns (no specific bills). | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 1 | 2017-08-11T09:16:31.547000-04:00 | |
| 2018934 | RED+BLUE STRATEGIES 8ac0c2fe-c42a-4d7c-bdf3-adcffac49bc2 | Q3 | RED+BLUE STRATEGIES | 400693064 | COHERUS BIOSCIENCES | 2017 | third_quarter | PHA | Work to reconsider current CMS position on the structure of the Medicare J-Code for biosimilar medications. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-09-27T16:38:57.697000-04:00 | |
| 2019393 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING c22efdea-f44c-41e4-8edc-c49a6257ee26 | Q3 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 35968 | SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2017 | third_quarter | PHA | Compounding of radiopharmaceuticals. | Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE | 10000 | 0 | 0 | 2017-10-03T11:32:14.850000-04:00 | |
| 2019595 | AMERICAN COLLEGE OF CLINICAL PHARMACY 90ddca98-51a5-4825-bc66-f73876dde068 | Q3 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2017 | third_quarter | PHA | Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 128375 | 0 | 0 | 2017-10-04T09:57:51.917000-04:00 | |
| 2020085 | RED+BLUE STRATEGIES 5fb896d7-47fa-4325-b2ab-eacdf7bfbed8 | Q3 | RED+BLUE STRATEGIES | 400693064 | EXPRESS SCRIPTS INC. | 2017 | third_quarter | PHA | S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-10-05T15:57:20.950000-04:00 | |
| 2020352 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM c3da4cb7-9edb-494a-8f67-f76d7fd32f07 | Q3 | ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 58534 | ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM | 2017 | third_quarter | PHA | Graham-Cassidy-Heller HR 1628. Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. | HOUSE OF REPRESENTATIVES,SENATE | 15335 | 0 | 0 | 2017-10-06T12:50:59.697000-04:00 | |
| 2020457 | PARRY, ROMANI, DECONCINI & SYMMS 9d1a9d70-4c30-4e42-a71d-98aa67fd7427 | Q3 | PARRY, ROMANI, DECONCINI & SYMMS | 30792 | ROCK & ASSOCIATES | 2017 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 12000 | 0 | 0 | 2017-10-06T15:34:34.887000-04:00 | |
| 2020924 | HOLLAND & KNIGHT LLP 74e70921-0b55-4f83-8721-7cad75d3ff48 | Q3 | HOLLAND & KNIGHT LLP | 18466 | THE BIOSIMILARS FORUM | 2017 | third_quarter | PHA | Medicare reimbursement issues, FDA regulation of biosimilars; S. 934, H.R. 2430, the FDA Reauthorization Act of 2017. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 120000 | 0 | 0 | 2017-10-09T15:40:15.367000-04:00 | |
| 2020927 | HOLLAND & KNIGHT LLP 8a5a8ae3-96d7-483b-85f3-3ee8ce814094 | Q3 | HOLLAND & KNIGHT LLP | 18466 | PROTECTING ACCESS TO PAIN RELIEF COALITION | 2017 | third_quarter | PHA | Advocating for policy to ensure patient access to pain relief. | 50000 | 0 | 0 | 2017-10-09T15:45:18.880000-04:00 | ||
| 2021164 | RED+BLUE STRATEGIES 7b10e64d-c25d-4541-b54c-d45115628e3e | Q3 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2017 | third_quarter | PHA | S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. Issues related to the price of prescription medications in the United States. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-10-10T11:26:11.380000-04:00 | |
| 2021266 | RED+BLUE STRATEGIES 6f7a834f-dc4b-45e1-9508-361f2ac6384c | Q3 | RED+BLUE STRATEGIES | 400693064 | PEW CHARITABLE TRUSTS | 2017 | third_quarter | PHA | S. 934 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy and delivery. H.R. 2430 - The FDA Reauthorization Act of 2017 - potential new policies related to prescription drug pricing, efficacy, and delivery. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement. Issues related opioid abuse and methods to fight against the opioid epidemic in the United States. Issues related to ensuring the safety of compounded medications. Issues related to over the counter medications and supplements. Issues related to the Physician Payment Sunshine Act and the Open Payments system. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-10-10T12:09:47.367000-04:00 | |
| 2021278 | POLITICAL CAPITAL, LLC 7a40af5a-bba6-4b2f-bfb5-7b090109e016 | Q3 | POLITICAL CAPITAL, LLC | 401104260 | MEDISCA INC | 2017 | third_quarter | PHA | DQSA Oversight HR 2871 | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2017-10-10T12:16:58.053000-04:00 | |
| 2021749 | ACG ADVOCACY f3f9fc2f-f4ae-4f7c-964a-c48755b57863 | Q3 | ACG ADVOCACY | 2057 | WALGREEN CO. | 2017 | third_quarter | PHA | Competition Policy Issues. | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 180000 | 0 | 0 | 2017-10-11T10:31:22.690000-04:00 | |
| 2021752 | KATE MOSS f72ebd00-7175-4634-b7a8-c4c3c97a6c00 | Q3 | KATE MOSS | 25988 | CVS HEALTH | 2017 | third_quarter | PHA | Legislation impacting PBMs and drug pricing | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2017-10-11T10:32:28.457000-04:00 | |
| 2022086 | RED+BLUE STRATEGIES 799bc279-5317-43c5-9e33-39a872ff0451 | Q3 | RED+BLUE STRATEGIES | 400693064 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS | 2017 | third_quarter | PHA | Issues related to curbing the abuse of opioids in the United States. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-10-11T14:39:58.013000-04:00 | |
| 2022107 | PRINTING INDUSTRIES OF AMERICA, INC. 51e5d953-c729-49df-ad6c-01a39f3fadb2 | Q3 | PRINTING INDUSTRIES OF AMERICA, INC. | 32203 | PRINTING INDUSTRIES OF AMERICA INC | 2017 | third_quarter | PHA | Printed pharmaceutical literature/labeling issues. | Environmental Protection Agency (EPA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Labor Relations Board (NLRB),Occupational Safety & Health Administration (OSHA),Securities & Exchange Commission (SEC),SENATE,U.S. Postal Service (USPS) | 80500 | 0 | 0 | 2017-10-11T14:51:08.997000-04:00 | |
| 2022132 | NELSON MULLINS RILEY & SCARBOROUGH cc1a9373-489a-4fef-981a-b3571b037362 | Q3 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | CASCADE HEMOPHILIA CONSORTIUM | 2017 | third_quarter | PHA | Issues related to 340B Drug Pricing Program | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-10-11T15:09:23.333000-04:00 | |
| 2022299 | INDEPENDENT PHARMACY COOPERATIVE cb2c8647-eba7-461e-b11c-412e55cb9ec3 | Q3 | INDEPENDENT PHARMACY COOPERATIVE | 313098 | INDEPENDENT PHARMACY COOPERATIVE | 2017 | third_quarter | PHA | Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" Support H.R. 2871 the "Preserving Patient Access to Compounded Medications Act of 2017 | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-10-11T19:03:04.707000-04:00 | |
| 2022379 | NELSON MULLINS RILEY & SCARBOROUGH 042d0564-737f-4c9b-8742-d316a1495195 | Q3 | NELSON MULLINS RILEY & SCARBOROUGH | 285871 | HEMOPHILIA OF GEORGIA | 2017 | third_quarter | PHA | Issues related to the 340B Drug Pricing Program and biomedical research | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-10-12T09:40:14.140000-04:00 | |
| 2022583 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) ae17d79d-8058-4b32-bbec-b8f4cac5afe4 | Q3 | MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) | 24486 | INOVIO PHARMACEUTICALS | 2017 | third_quarter | PHA | Government Relations Services including developing strategies to achieve legislative goals | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-10-12T11:23:17.987000-04:00 | |
| 2022888 | MR. VINCENT A. PANVINI 77bf5b20-efe5-4b13-adbc-ef0bf89821c0 | Q3 | MR. VINCENT A. PANVINI | 401008845 | PHRMA | 2017 | third_quarter | PHA | Illegal Pharmaceutical Importation PDUFA- Prescription Drug User Fee Act | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2017-10-12T15:08:03.163000-04:00 | ||
| 2023003 | POLITICAL CAPITAL, LLC f8e6f685-3258-429a-b9b3-0d1b2b09126c | 3A | POLITICAL CAPITAL, LLC | 401104260 | PINE PHARMACEUTICALS | 2017 | third_quarter | PHA | Outsourcing Facilities HR-2871 | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2017-10-12T15:46:08.543000-04:00 | ||
| 2023250 | MCDERMOTT+ LLC 2bdd2d99-94b2-40fc-8017-bab0ba8197e2 | Q3 | MCDERMOTT+ LLC | 401103287 | ALLIANCE FOR RURAL HOSPITAL ACCESS | 2017 | third_quarter | PHA | Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2017-10-13T09:35:00.297000-04:00 | |
| 2023621 | MERCURY PUBLIC AFFAIRS, LLC 40e9e86b-cfec-47f9-8e82-b9351cccbe27 | Q3 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | KALISPELL REGIONAL HEALTHCARE | 2017 | third_quarter | PHA | Veteran pharmacy issues and polices | Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 30000 | 0 | 0 | 2017-10-13T14:00:39.947000-04:00 | |
| 2023677 | MERCURY PUBLIC AFFAIRS, LLC 8e8e0ed9-4545-4855-9442-6b0f9fce5e06 | Q3 | MERCURY PUBLIC AFFAIRS, LLC | 70175 | MORRIS AND DICKSON | 2017 | third_quarter | PHA | IT Help RE Improper Prescriptions | Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS) | 20000 | 0 | 0 | 2017-10-13T14:28:19.877000-04:00 | |
| 2023786 | FORGE FEDERAL AFFAIRS LLC 383cb981-286f-433e-bfc6-82abf342602f | Q3 | FORGE FEDERAL AFFAIRS LLC | 400865535 | LILLY USA LLC | 2017 | third_quarter | PHA | Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act. P.L.115-52, FDA Reauthorization Act of 2017. | HOUSE OF REPRESENTATIVES | 20000 | 0 | 0 | 2017-10-13T15:08:26.677000-04:00 | |
| 2023789 | ACADEMY OF MANAGED CARE PHARMACY 70f65bde-06ef-4f03-acc4-ebeef51b20b8 | Q3 | ACADEMY OF MANAGED CARE PHARMACY | 48793 | ACADEMY OF MANAGED CARE PHARMACY | 2017 | third_quarter | PHA | Letters of support for the CREATES Act (H.R. 2212 and S. 974), (H.R. 3545) The Overdose Prevention and Patient Safety Act and the Pharmaceutical Information Exchange Act(H.R. 2026). Comments to FDA on Hatch-Waxman reform to advocate for prohibition of strategies that unnecessarily delay the entry of generic drugs into the marketplace. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2017-10-13T15:08:28.210000-04:00 | |
| 2024134 | BROYDRICK & ASSOCIATES c8ad5ca1-e0a7-48b8-bd71-88a2b5e9ca82 | Q3 | BROYDRICK & ASSOCIATES | 7268 | TONIX PHARMACEUTICALS | 2017 | third_quarter | PHA | Funding for a new drug for PTSD. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2017-10-15T16:07:27.727000-04:00 | |
| 2024317 | NOVO NORDISK INC. 6aaa857e-0e24-4b29-beda-0cd42e6fdc79 | Q3 | NOVO NORDISK INC. | 284790 | NOVO NORDISK INC. | 2017 | third_quarter | PHA | Issues related to H.R. 2430/S. 934 FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; issues related to 340B program | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE | 790000 | 0 | 0 | 2017-10-16T10:09:53.430000-04:00 | |
| 2024431 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 5154bb88-8f34-44da-82ef-3c0947001eee | Q3 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | 11003 | COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE | 2017 | third_quarter | PHA | Oppose Rep. Carter's DIR Letter Oppose H.R 218: King Cove Road Land Exchange Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2017-10-16T10:47:57.780000-04:00 | |
| 2024488 | AKIN GUMP STRAUSS HAUER & FELD 5222be7d-8ffa-4c37-a765-637003c87daf | Q3 | AKIN GUMP STRAUSS HAUER & FELD | 682 | PHARMEDIUM SERVICES, LLC | 2017 | third_quarter | PHA | Drug Quality and Security Act, Pub. L. 113-54; FDA regulatory implementation of Section 503B of the Food, Drug and Cosmetic Act; FDA Pharmacy Compounding Advisory Committee; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-10-16T10:57:33.780000-04:00 | |
| 2024557 | DAVE KOLBE CONSULTING 7a8c5238-9c5f-439d-855a-e7dabad9bacf | Q3 | DAVE KOLBE CONSULTING | 401104329 | PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | 2017 | third_quarter | PHA | Medicare Part-D rebates Trade agreements Patent reform issues Prescription Drug User Fee Act (PDUFA) | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-10-16T11:19:38.703000-04:00 | |
| 2024592 | AMERICAN CONSERVATIVE UNION f4b97c11-d2c8-4f07-8486-273b2e5f4032 | Q3 | AMERICAN CONSERVATIVE UNION | 62712 | AMERICAN CONSERVATIVE UNION | 2017 | third_quarter | PHA | S.974 - CREATES Act of 2017 H.R.2212 - CREATES Act of 2017 | Federal Communications Commission (FCC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),SENATE,White House Office | 10000 | 0 | 0 | 2017-10-16T11:31:13.690000-04:00 | |
| 2024620 | MANATT, PHELPS, AND PHILLIPS 7fe789a1-e887-463e-ae81-395ff0295349 | Q3 | MANATT, PHELPS, AND PHILLIPS | 23645 | NEKTAR THERAPEUTICS | 2017 | third_quarter | PHA | FDA oversight of certain pain reliever products | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2017-10-16T11:34:24.440000-04:00 | ||
| 2025087 | HANCE SCARBOROUGH da2d86be-1ca2-4267-a1e3-693c09190f8a | Q3 | HANCE SCARBOROUGH | 17443 | ALLIANCE FOR PHARMACY COMPOUNDING | 2017 | third_quarter | PHA | Issues related to the regulation of pharmacy compounding. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-10-16T14:08:08.480000-04:00 | |
| 2025497 | WINNING STRATEGIES WASHINGTON f7d6f86b-4e75-489c-93eb-b788ce3dc79e | Q3 | WINNING STRATEGIES WASHINGTON | 50796 | KALEO | 2017 | third_quarter | PHA | Pharmaceutical drug development including epinephrine for anaphylaxis | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE | 30000 | 0 | 0 | 2017-10-16T14:57:04.083000-04:00 | |
| 2025533 | PENN AVENUE PARTNERS 686e540d-c981-4fad-929a-af1d6f01d892 | Q3 | PENN AVENUE PARTNERS | 400918672 | PURDUE PHARMA L.P. | 2017 | third_quarter | PHA | Monitoring legislative and regulatory activities impacting the pharmaceutical industry. | SENATE | 60000 | 0 | 0 | 2017-10-16T15:02:32.100000-04:00 | |
| 2025651 | ANIMAL HEALTH INSTITUTE 27651a7b-1601-4acb-bce3-c190666f447d | Q3 | ANIMAL HEALTH INSTITUTE | 4037 | ANIMAL HEALTH INSTITUTE | 2017 | third_quarter | PHA | Issues related to illegal drug manufacturing under the guise of pharmacy compounding; Issues related to the granting of Categorical Exclusions for animal health products. | Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR) | 35000 | 0 | 0 | 2017-10-16T15:28:39.930000-04:00 | |
| 2025783 | FORBES-TATE 7cd416c6-e379-447b-b4d5-09d1c695829d | Q3 | FORBES-TATE | 400976792 | PHRMA | 2017 | third_quarter | PHA | Issues pertaining to Rx Drug pricing. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2017-10-16T16:03:57.480000-04:00 | |
| 2026206 | WAXMAN STRATEGIES 7b334589-2757-4ea5-8194-3a0e82f15eb4 | Q3 | WAXMAN STRATEGIES | 401103693 | 340B HEALTH | 2017 | third_quarter | PHA | Issues affecting the 340B drug pricing program | HOUSE OF REPRESENTATIVES | 18750 | 0 | 0 | 2017-10-17T09:12:29.677000-04:00 | |
| 2026677 | THE INGRAM GROUP LLC 17b6d6a8-bb39-4e35-8163-117e505a66c9 | Q3 | THE INGRAM GROUP LLC | 400577737 | ELI LILLY AND COMPANY | 2017 | third_quarter | PHA | General issues related to the biopharmaceutical and pharmaceutical industries including drug importation. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-10-17T11:19:31.803000-04:00 | |
| 2026860 | AVENUE SOLUTIONS 24dfea5f-8918-464e-910f-2b1d83b8bdab | Q3 | AVENUE SOLUTIONS | 72111 | JAZZ PHARMACEUTICALS, INC. | 2017 | third_quarter | PHA | H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2017 (CREATES Act of 2017); H.R. 2051, FAST Generics Act | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-10-17T12:09:22.950000-04:00 | |
| 2027122 | AVENUE SOLUTIONS f051bbe4-eeeb-4be7-8625-78a3afe3a503 | Q3 | AVENUE SOLUTIONS | 72111 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 2017 | third_quarter | PHA | Issues related to biosimilars | 80000 | 0 | 0 | 2017-10-17T13:17:14.927000-04:00 | ||
| 2027144 | AVENUE SOLUTIONS cb256bbd-4122-480d-ae92-8322b2494809 | Q3 | AVENUE SOLUTIONS | 72111 | MOMENTA PHARMACEUTICALS, INC. | 2017 | third_quarter | PHA | Improving access to biogenerics | 50000 | 0 | 0 | 2017-10-17T13:22:30.817000-04:00 | ||
| 2027172 | SQUIRE PATTON BOGGS 35e46449-2d1a-4c62-af4b-d73fd7fc4407 | Q3 | SQUIRE PATTON BOGGS | 30906 | BIOTECHNOLOGY INNOVATION ORGANIZATION | 2017 | third_quarter | PHA | Monitoring legislation that could impact pharmaceutical industry. | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 80000 | 0 | 0 | 2017-10-17T13:29:52.473000-04:00 | |
| 2027208 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 55a5ade0-8186-4f9f-a374-46d05436fd84 | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | AMERICAN SOCIETY OF HEMATOLOGY | 2017 | third_quarter | PHA | HR 1409, Cancer Drug Coverage Parity Act | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 30000 | 0 | 0 | 2017-10-17T13:35:10.350000-04:00 | |
| 2027231 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 2a84c594-b784-4943-8bc2-55f056ffd52f | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL ASSOCIATION OF EPILEPSY CENTERS | 2017 | third_quarter | PHA | Issues related to anti-epileptic drugs. | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 10000 | 0 | 0 | 2017-10-17T13:36:14.210000-04:00 | |
| 2027244 | SORINI, SAMET & ASSOCIATES, LLC dcaf6adc-5738-4e0a-8fd1-42af38536ad2 | Q3 | SORINI, SAMET & ASSOCIATES, LLC | 317754 | PETSMART, INC. | 2017 | third_quarter | PHA | Veterinary prescriptions | Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,Intl Trade Administration (ITA),SENATE,U.S. International Trade Commission (ITC) | 20000 | 0 | 0 | 2017-10-17T13:40:23.537000-04:00 | |
| 2027249 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. ba5a919f-80ec-4165-8b60-9ed9add90b7a | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL HEMOPHILIA FOUNDATION | 2017 | third_quarter | PHA | Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2017-10-17T13:40:24.837000-04:00 | |
| 2027304 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. e1f630f5-91e5-4903-90de-ea11b761385e | Q3 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | THE HEMOPHILIA ALLIANCE | 2017 | third_quarter | PHA | Issues related to the 340B drug discount program | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-10-17T13:51:55.210000-04:00 | |
| 2027786 | PD FRAZER CONSULTING, INC. e62d3f0a-f34d-429d-82fa-bed56f8fe42e | Q3 | PD FRAZER CONSULTING, INC. | 65998 | CANADA INTERNATIONAL PHARMACY ASSOCIATION | 2017 | third_quarter | PHA | Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2017-10-17T15:40:58.270000-04:00 | |
| 2027836 | PUBLIC CITIZEN b2e7ff17-ad83-4309-823d-51ce6ec5e573 | Q3 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2017 | third_quarter | PHA | S 934/HR 2430-FDA re-authorization Act of 2017, S 974/HR 2212-CREATES Act, S 771/HR 1776-Improving access to affordable prescription drugs act, S 204-Trickett Wendler Right to try act of 2017, S 1509/HR 1223-OPEN act, S 1369/HR 2974-Stop Price Gouging Act, Preserve access to affordable generics act, HR 205-to amend the Food, Drug & Cosmetic Act to require labeling of genetically engineered fish, S 495-Medicaid Innovation Price Fund Act, S 252-Medicaid Drug Savings Act of 2017,S 1131/HR 2439-Fair Accountability and Innovative Research Drug Pricing Act of 2017, HR 1628-American Health Care Act of 2017, S 297-Increasing Competition in Pharmaceuticals Act, HR 749 Lower drugs through Competition act, S 1390-stronger patents act of 2017, S 168/HR 3536-A bill to require persons who undertake federally funded research and development of drugs to enter into reasonable pricing agreements with Secretary of HHS. | Consumer Product Safety Commission (CPSC),Federal Communications Commission (FCC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR) | 70000 | 0 | 0 | 2017-10-17T15:46:23.960000-04:00 | |
| 2028435 | CONNECT 4 STRATEGIES, LLC b461cb9b-bb1a-433f-83ae-dde5e55ec9f4 | Q3 | CONNECT 4 STRATEGIES, LLC | 401103720 | OREXO US, INC. | 2017 | third_quarter | PHA | s916 Access to Emergency Medications Act | SENATE | 20000 | 0 | 0 | 2017-10-17T20:04:30.357000-04:00 | |
| 2028482 | CHATMAN, LLC 33e2dd2d-cbda-4607-b4ce-e9d8bfb042f3 | Q3 | CHATMAN, LLC | 400678024 | LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER | 2017 | third_quarter | PHA | Support continuation of Pharmacy 340B program in HRSA. Provide comments to FDA proposed rule change. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-10-17T22:34:07.140000-04:00 | |
| 2028532 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 76dfdf4d-781c-4c48-a4e9-74c5a26ad22e | Q3 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2017 | third_quarter | PHA | Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 176000 | 0 | 0 | 2017-10-18T08:58:59.663000-04:00 | |
| 2028941 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 629f73e5-feb9-436d-99de-1d9103134c5e | Q3 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | CHILDREN'S NATIONAL MEDICAL CENTER | 2017 | third_quarter | PHA | Representation on health-related issues including reimbursement, research, public-health & clinical care | Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 50000 | 0 | 0 | 2017-10-18T10:30:12.283000-04:00 | |
| 2029470 | BLUECROSS BLUESHIELD OF TENNESSEE dab2ed1d-7357-4735-acf4-3b8d53803ce2 | Q3 | BLUECROSS BLUESHIELD OF TENNESSEE | 6440 | BLUECROSS BLUESHIELD OF TENNESSEE | 2017 | third_quarter | PHA | General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-10-18T11:49:33.347000-04:00 | |
| 2029638 | ROCK & ASSOCIATES 125d504c-ffd5-402b-9afb-f5b773c0f028 | Q3 | ROCK & ASSOCIATES | 33545 | BRAIDWOOD MANAGEMENT, INC. | 2017 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-10-18T12:29:15.123000-04:00 | |
| 2029641 | ROCK & ASSOCIATES 574a0d61-84f1-4ab3-87a0-34c8aaf9b702 | Q3 | ROCK & ASSOCIATES | 33545 | DIAMONDBACK DRUGS | 2017 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-10-18T12:30:16.357000-04:00 | |
| 2029647 | ROCK & ASSOCIATES e7093e79-2bb6-450c-8d09-4e59b35bc28f | Q3 | ROCK & ASSOCIATES | 33545 | VETERINARY PHARMACIES OF AMERICA, INC. | 2017 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-10-18T12:31:22.843000-04:00 | |
| 2029651 | WELLINGTON STRATEGIES, LLC. f6e211fc-fe9c-4147-ae83-18b412da86ca | 3T | WELLINGTON STRATEGIES, LLC. | 401104410 | OMNICELL, INC. | 2017 | third_quarter | PHA | Regulations pertaining to the Drug Quality and Security Act (Public Law No: 113-54) | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 15000 | 0 | 1 | 2017-10-18T12:33:25.453000-04:00 | |
| 2029653 | ROCK & ASSOCIATES e23ea653-3c67-42fa-8aff-0507a17702ac | Q3 | ROCK & ASSOCIATES | 33545 | WEDGEWOOD VILLAGE PHARMACY, INC. | 2017 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-10-18T12:33:26.857000-04:00 | |
| 2029659 | ROCK & ASSOCIATES 7f912400-10ab-4d24-ab34-d85dd5cabdbf | Q3 | ROCK & ASSOCIATES | 33545 | WOMEN'S INTERNATIONAL PHARMACY | 2017 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-10-18T12:36:32.360000-04:00 | |
| 2029663 | ROCK & ASSOCIATES bb9bccc6-76a2-4a1f-ac2d-aa950cab4212 | Q3 | ROCK & ASSOCIATES | 33545 | WELLNESS PHARMACY | 2017 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-10-18T12:37:33.843000-04:00 | |
| 2029667 | ROCK & ASSOCIATES a16b4722-d83e-4446-830d-098db682f9c7 | Q3 | ROCK & ASSOCIATES | 33545 | PRECISION PHARMACY | 2017 | third_quarter | PHA | Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. | HOUSE OF REPRESENTATIVES,SENATE | 11250 | 0 | 0 | 2017-10-18T12:38:37.797000-04:00 | |
| 2029713 | OREGON HEALTH & SCIENCE UNIVERSITY 91609100-a51d-4291-af2f-bb96763730d8 | Q3 | OREGON HEALTH & SCIENCE UNIVERSITY | 30291 | OREGON HEALTH & SCIENCE UNIVERSITY | 2017 | third_quarter | PHA | 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2017-10-18T12:58:05.970000-04:00 | |
| 2029893 | THERMO FISHER SCIENTIFIC INC. 15bbfbdd-361f-49cc-939a-f966dd26c91a | Q3 | THERMO FISHER SCIENTIFIC INC. | 323251 | THERMO FISHER SCIENTIFIC INC | 2017 | third_quarter | PHA | Drug shortage prevention Abuse-deterrent pseudophedrine | Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),SENATE | 310000 | 0 | 0 | 2017-10-18T13:50:39.320000-04:00 | |
| 2029919 | AMERICAN PHARMACISTS ASSOCIATION da444c66-a1ba-4fd8-8436-16df0ca32260 | Q3 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2017 | third_quarter | PHA | HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes. HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services. HR 1480 Safe and Affordable Drugs from Canada Act of 2017 S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes. S 778 Prescription Drug Monitoring Act of 2017 HR 934 Personal Drug Importation Fairness Act of 2017 HR 421 Allowing Greater Access to Safe and Effective Contraception Act HR 1436 To provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017. HR 1245, S 469 To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals. HR 3268 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2018 (drug compounding provisions) S 1079 Protecting Americans from Dangerous Opioids Act HR 2430 FDA Reauthorization Act of 2017 HR 2567 Access to Birth Control Act HR 2871 Preserving Patient Access to Compounded Medications Act of 2017 HR 2063 Opioid PACE Act of 2017 S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017 S 469 Affordable and Safe Prescription Drug Importati… | HOUSE OF REPRESENTATIVES,SENATE | 34000 | 0 | 0 | 2017-10-18T13:56:53.603000-04:00 | |
| 2029956 | NATIONAL NURSES UNITED d53b0622-f436-4c6f-89c3-45a13eb0829c | Q3 | NATIONAL NURSES UNITED | 40021153 | NATIONAL NURSES UNITED | 2017 | third_quarter | PHA | H.R. 1245 - support for Affordable & Safe Prescription Drug Importation Act H.R. 1776 - support for Improving Access to Affordable Prescription Drugs Act S. 469 - support for Affordable and Safe Prescription Drug Importation Act | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-10-18T14:04:13.417000-04:00 | |
| 2030005 | ACG ADVOCACY 0325964b-2fdc-4b87-9407-8be82b22bc77 | Q3 | ACG ADVOCACY | 2057 | NATIONAL ASSOCIATION OF CHAIN DRUG STORES | 2017 | third_quarter | PHA | Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. Advocating for coverage of pharmacists services under Medicare Part B. Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. Advocating for fair and accurate Medicaid pharmacy reimbursement. Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management. Issues related to pharmacy reimbursement for 21st Century Cures. Issues regarding TriCare coverage for pharmacies. Issues regarding direct and indirect renumeration under Medicare Part D plans. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2017-10-18T14:08:35.370000-04:00 | |
| 2030010 | MWW GROUP ec82dd64-fa73-403c-b668-a5abdcf9bc1d | Q3 | MWW GROUP | 26318 | UNITED PHARMACY PARTNERS, INC. (UPPI) | 2017 | third_quarter | PHA | Nuclear pharmacy reimbursement; Conversion to Low Enriched Uranium (LEU) | 10000 | 0 | 0 | 2017-10-18T14:09:38.713000-04:00 | ||
| 2030017 | ACG ADVOCACY eac501fa-e1a9-48b2-8218-271b1e4a5be3 | Q3 | ACG ADVOCACY | 2057 | ROIVANT SCIENCES, INC. | 2017 | third_quarter | PHA | Drug Pricing. Innovation Issues. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2017-10-18T14:10:42.247000-04:00 | |
| 2030177 | KOUNTOUPES DENHAM CARR & REID, LLC 9f035a32-82a1-445f-a61c-2dbeba728b8f | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2017 | third_quarter | PHA | General issues related to over the counter pharmaceuticals, cosmetics issues related to Rx/OTC transition issues related to draft legislation addressing the over the counter drug monograph process, and H. R. 2430, the FDA Reauthorization Act (FDARA) of 2017. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-10-18T14:41:17.140000-04:00 | |
| 2030183 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. 5e00fc37-1148-420a-b6b5-0bef0195d617 | Q3 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 4653 | ASSOCIATION OF NATIONAL ADVERTISERS, INC. | 2017 | third_quarter | PHA | Proposals relating to the regulation of direct-to-consumer prescription drug advertising | Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of | 420000 | 0 | 0 | 2017-10-18T14:42:24.187000-04:00 | |
| 2030438 | KOUNTOUPES DENHAM CARR & REID, LLC 30383b92-2009-4d0f-92dc-8c251174d2bc | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | CVS HEALTH | 2017 | third_quarter | PHA | General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.974 and H. R. 2212, The CREATES Act. Issues related to drug pricing such as S.771 and H.R. 1776, The Improving Access to Affordable Drugs Act. Issues related to opioid abuse. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-10-18T15:04:52.173000-04:00 | |
| 2031304 | KOUNTOUPES DENHAM CARR & REID, LLC 192b8d52-6451-42e3-b6b1-695a404e02e4 | Q3 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) | 2017 | third_quarter | PHA | Policy matters related to generic pharmaceuticals and biosimilars, including reauthorization of the Generic Drug User Fee Agreement, reauthorization of the Biosimilar User Fee Agreement, H.R. 2051, The FAST Generic Act of 2017, S.771 and H.R. 1776, Improving Access to Affordable Drugs, and changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Issues related to drug takeback and opioid addition. Issues realted to H. R. 2212 and S. 974, CREATES Act of 2017. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 60000 | 0 | 0 | 2017-10-18T17:38:30.503000-04:00 | |
| 2031349 | UNIVERSITY OF IOWA c942868e-aa79-4f10-8b08-06acd0331d1e | Q3 | UNIVERSITY OF IOWA | 49191 | UNIVERSITY OF IOWA | 2017 | third_quarter | PHA | FY 17 and FY 18 appropriations for NIH Support for palliative care programs Support for 340B program | Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Energy, Dept of,Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT) | 86662 | 0 | 0 | 2017-10-18T17:58:54.163000-04:00 | |
| 2031412 | ISEMAN & ASSOCIATES LLC 0f5cf7aa-0a3c-4605-8dc9-644519fc3a02 | Q3 | ISEMAN & ASSOCIATES LLC | 401103582 | TICHENOR VENTURES, LLC | 2017 | third_quarter | PHA | Monitoring biotech legislation | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2017-10-18T18:14:20.273000-04:00 | |
| 2031552 | WEST FRONT STRATEGIES LLC fd18ef04-2430-4956-baa2-0e93f58e1b3a | Q3 | WEST FRONT STRATEGIES LLC | 401103493 | WALGREEN CO. | 2017 | third_quarter | PHA | Pharmacy and Medically Underserved Areas Enhancement Act (S. 109 and HR 592), to amend Title IIX of the Social Security Act to allow pharmacists to be reimbursed under Medicare Part B for services provided to patients in medically underserved areas. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-10-18T20:44:36.227000-04:00 | |
| 2031964 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3dd1df4a-6dfb-4ad7-8ef9-2376199860c6 | Q3 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2017 | third_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE | 115000 | 0 | 0 | 2017-10-19T09:30:37.763000-04:00 | |
| 2032095 | APOTEX CORP. ce5fc93c-8e31-4a48-b482-c888e9c6fef4 | Q3 | APOTEX CORP. | 310973 | APOTEX CORP. | 2017 | third_quarter | PHA | HR 2430, the FDA Reauthorization Act of 2017, Title VIII, Improving Generic Drug Access, provisions relating to enhancing the generic drug approval process, spurring the development and approval of generic versions of drugs with limited competition, and generic drug exclusivity; and HR 2212/S. 974, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, and HR 2051, the Fair Access for Safe and Timely Generic Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals. | HOUSE OF REPRESENTATIVES,SENATE | 110000 | 0 | 0 | 2017-10-19T09:46:26.920000-04:00 | |
| 2032156 | ELI LILLY AND COMPANY 3e090c12-29e6-43b4-b4b3-4a4982d18b80 | Q3 | ELI LILLY AND COMPANY | 13392 | ELI LILLY AND COMPANY | 2017 | third_quarter | PHA | Hospital discounts; 340B program | Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR) | 2020000 | 0 | 0 | 2017-10-19T09:52:52.390000-04:00 | |
| 2032451 | POWERS PYLES SUTTER & VERVILLE, P.C. 87bd9691-3b78-446e-8480-5a34215320c9 | Q3 | POWERS PYLES SUTTER & VERVILLE, P.C. | 32008 | 340B HEALTH | 2017 | third_quarter | PHA | Section 340B of the Public Health Services Act, Section 1927 of the Social Security Act and issues related to (1) administration and Congressional oversight of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, and (3)finding of the Health Resources and Services Administration (HRSA) under the Labor Health & Human Services & education appropriations bills. | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2017-10-19T10:32:21.270000-04:00 | |
| 2032527 | AMERICAN VETERINARY MEDICAL ASSOCIATION 71a583dd-cfd2-4f49-9d5a-b18f30aed21a | Q3 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2017 | third_quarter | PHA | H.R. 623 Fairness to Pet Owners Act Veterinary Compounding Draft Legislation | Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE | 230000 | 0 | 0 | 2017-10-19T10:38:04.240000-04:00 | |
| 2032560 | AMERICAN VETERINARY MEDICAL ASSOCIATION 3fb06de5-92f2-494d-9845-b0d4698ba6ab | Q3 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 3630 | AMERICAN VETERINARY MEDICAL ASSOCIATION | 2017 | third_quarter | PHA | H.R. 623 Fairness to Pet Owners Act Veterinary Compounding Draft Legislation | Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE | 230000 | 0 | 0 | 2017-10-19T10:39:15.520000-04:00 | |
| 2032727 | BUCHANAN INGERSOLL & ROONEY PC cb735764-282e-4ca1-8cf8-806cccd534d7 | Q3 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | 60 DEGREES PHARMACEUTICALS | 2017 | third_quarter | PHA | Government relations services relating to priority review voucher within the user fee reauthorization legislation (S.934/HR2430). | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2017-10-19T10:55:47.023000-04:00 | ||
| 2032770 | GREATER NEW YORK HOSPITAL ASSOCIATION c5b8d8ac-1644-4fe0-b333-1abbda2589ab | Q3 | GREATER NEW YORK HOSPITAL ASSOCIATION | 16830 | GREATER NEW YORK HOSPITAL ASSOCIATION | 2017 | third_quarter | PHA | Preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; educating policymakers on hospital drug shortages and significant drug price increases. Support drug pricing legislation that would promote competition by fast tracking generic drug applications (H.R. 749/S.297). Oppose legislation that would harm the 340B drug discount program for safety net hospitals. Support reforms aimed at creating more competition in the generic drug market, including ending pay for delay (S.124) and prohibiting REMS abuses (S.944/H.R.2214) | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office | 600000 | 0 | 0 | 2017-10-19T11:01:10.100000-04:00 | |
| 2032785 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS f43ce5e2-d6b8-48ee-9b46-f0c00968b8ec | 3A | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 3457 | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2017 | third_quarter | PHA | Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE | 130000 | 0 | 0 | 2017-10-19T11:02:15.820000-04:00 | |
| 2032961 | CROSSROADS STRATEGIES, LLC e1082b4f-784b-4e96-b3d6-3bcdac0d8a71 | Q3 | CROSSROADS STRATEGIES, LLC | 400531586 | ALITHEON, INC. | 2017 | third_quarter | PHA | Issues related to the elimination of counterfeit pharmaceuticals. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Agency for International Development (USAID) | 30000 | 0 | 0 | 2017-10-19T11:23:05.040000-04:00 | |
| 2033151 | BUCHANAN INGERSOLL & ROONEY PC 47834e65-e339-43eb-b02c-3f1a36b4f5b0 | Q3 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | TONIX PHARMACEUTICALS HOLDING CORP. | 2017 | third_quarter | PHA | Federal funding related to clinical trials for military PTSD; FY 2018 NDAA and Defense Appropriations | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2017-10-19T11:46:00.170000-04:00 | |
| 2033217 | PRIME THERAPEUTICS b51fd801-10b3-45cf-ab29-a87134ec572b | Q3 | PRIME THERAPEUTICS | 400339576 | PRIME THERAPEUTICS | 2017 | third_quarter | PHA | H.R.2430/S.934: FDA Reauthorization Act of 2017--provisions to ensure greater market competition for generics & biosimilars. S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums. H.R.1703: Medical Product Communications Act of 2017--provisions relating to greater market access for off-label indications. H.R. 3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). H.R.3447: Furthering Access to Coordinated Treatment for Seniors Act of 2017--provisions to provide prescription drug plans with Medicare Parts A and B data. Draft legislation "to amend title XVIII of the Social Security Act to provide for electronic prior authorization under Medicare Part D for covered part D drugs and for other purposes" (House only). | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2017-10-19T11:51:35.547000-04:00 | |
| 2033322 | BUCHANAN INGERSOLL & ROONEY PC 2a81af43-baa1-4e60-a040-1e1c4290fb48 | Q3 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | WOMEN'S CHOICE PHARMACEUTICALS, LLC | 2017 | third_quarter | PHA | Development of government relations strategy relating to prenatal dietary supplements. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-10-19T12:00:39.310000-04:00 | |
| 2033535 | KING & SPALDING LLP 47a8e406-a03d-4b10-85f6-ef19ce2c8a5d | Q3 | KING & SPALDING LLP | 21632 | SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) | 2017 | third_quarter | PHA | Issues related to inclusion of prescription drugs within Essential Health Benefit and mental health coverage expansion | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2017-10-19T12:20:27.500000-04:00 | |
| 2033673 | BARNES & THORNBURG, LLP 57f86381-8fac-49d6-afe8-7a433501cc4c | 3T | BARNES & THORNBURG, LLP | 5404 | CVS HEALTH | 2017 | third_quarter | PHA | Regulations affecting chain drug stores, pharmacy benefit managers and tax issues. | Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,Vice President of the U.S. | 50000 | 0 | 1 | 2017-10-19T12:37:50.707000-04:00 | |
| 2034077 | MASSACHUSETTS MEDICAL SOCIETY 45afe3ee-8ed1-4428-9455-27412e62ddf6 | Q3 | MASSACHUSETTS MEDICAL SOCIETY | 23975 | MASSACHUSETTS MEDICAL SOCIETY | 2017 | third_quarter | PHA | S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2017-10-19T13:11:13.523000-04:00 | |
| 2034308 | BALLARD PARTNERS f595d4b6-5648-41ff-8e1a-2a8dd7be8f9b | Q3 | BALLARD PARTNERS | 401104288 | LABORATORY CORPORATIONS OF AMERICA HOLDINGS | 2017 | third_quarter | PHA | The registrant will advise and advocate for the client on general government policies and regulations. | Health & Human Services, Dept of (HHS),White House Office | 40000 | 0 | 0 | 2017-10-19T13:32:29.387000-04:00 | |
| 2034353 | SC PARTNERS LLC 7508cc30-d7dd-4da7-904e-a3b39532e06f | Q3 | SC PARTNERS LLC | 318994 | PFIZER, INC. | 2017 | third_quarter | PHA | Advocated for maintaining a safe prescription drug supply, and shared concerns about the safety and economic implications of allowing the importation of prescription drugs and biologics from Canada and other countries. Affordable and Safe Prescription Drug Importation Act (S. 469) | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2017-10-19T13:36:59.480000-04:00 | |
| 2034443 | BLUE CROSS AND BLUE SHIELD ASSOCIATION f1c6be0c-94da-4c7e-884f-0be5c72b12b2 | Q3 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 6358 | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2017 | third_quarter | PHA | Drug Pricing; | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Vice President of the U.S.,White House Office | 2040000 | 0 | 0 | 2017-10-19T13:41:38.277000-04:00 | |
| 2034537 | FARRAGUT PARTNERS LLP 99c61f61-e600-4cd8-86f0-976449fbc356 | Q3 | FARRAGUT PARTNERS LLP | 401103938 | AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS | 2017 | third_quarter | PHA | Issues pertaining to Prescription Drug Monitoring programs. Public Health. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2017-10-19T13:49:27.480000-04:00 | |
| 2034563 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION fd18181b-5694-4b49-be92-8285b8d11af0 | Q3 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 31348 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 2017 | third_quarter | PHA | Issues related to pharmacy contracting with respect to drug pricing and pharmacy networks. Regulatory and proposed legislative changes to Medicare Part D pharmacy contracting, Direct and Indirect Remuneration (DIR), pharmacy networks, and mail-service pharmacy. Issues related to the management of Medicaid prescription drug benefits. Issues related to prescription drug abuse. Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as PBM disclosure provisions, implementation of the prescriber registration rules and definition of negotiated price. HR.1038/S.413, Improving Transparency and Accuracy in Part D Spending Act H.R.1316, Prescription Drug Price Transparency Act S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 S.771, Improving Access to Affordable Prescription Drug Act H.R.1939/S.1044, Ensuring Seniors Access to Local Pharmacies Act H.R.3528, The Every Prescription Carried Safely Act | Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),SENATE | 746720 | 0 | 0 | 2017-10-19T13:50:39.637000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);